News

Paving the Way for Innovation

Dr. Christopher Flowers is passionate about working as a team and sharing with others the same enthusiasm for medicine that he has had since the onset of his career.

An Enduring Legacy of Hope and Impact

Chike Springer was many things — a husband, son, brother, uncle and patriot — but he was most known for his positivity and determination.

U.S. Food and Drug Administration Approves Loncastuximab Tesirine-lpyl for Large B-cell Lymphoma

Loncastuximab tesirine-lpyl is the first and only CD-19-directed antibody drug conjugate single agent approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Ask the Doctor: How can we determine the efficacy of the COVID-19 vaccine and how we may respond?

As the rollout of the new COVID-19 vaccines continues, there is constant new data related…

Ask the Doctor: How do physicians determine when follicular lymphoma has transformed to DLBCL? What kind of tests or symptoms help doctors monitor this?

Transformed lymphoma occurs when an indolent lymphoma turns into a more aggressive one. A transformation…

LRF Honors Michael E. Williams, MD with Mantle Cell Lymphoma Leadership Award

World-renowned hematologist/oncologist receives inaugural award for outstanding commitment in the field of mantle cell lymphoma research and patient care.

Ask the Doctor: What is the current efficacy of oral therapies for marginal zone lymphoma?

There are several chemotherapy and targeted anticancer drugs approved or under investigation for the treatment…

Lymphoma Research Foundation Funds 29 New Grants Investigating Lymphoma and Chronic Lymphocytic Leukemia, Introduces Expanded Research Program and Health Equity Initiative

Investment supports early-career scientists dedicated to developing patient therapies and lymphoma cures.

Lymphoma Research Foundation Unites Lymphoma Community Nationwide Through Lymphoma Walk Program, Walk On! America

Thousands to Raise Awareness and Funds through Virtual Celebration and Socially Distanced Neighborhood Walks The Lymphoma Research Foundation…

U.S. Food and Drug Administration Approves CAR T Cell Therapy for Follicular Lymphoma

Axicabtagene ciloeucel has been approved for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).